Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor - Wikidata - wikimedia - TriplyDB

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

http://www.wikidata.org/entity/Q34165500

about

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival Androgen receptor variants occur frequently in castration resistant prostate cancer metastases Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Advances in genetics: widening our understanding of prostate cancer Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Clonal origin and spread of metastatic prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Androgen receptor footprint on the way to prostate cancer progression New drugs for prostate cancer Abiraterone in prostate cancer: a new angle to an old problem Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Androgen receptor on the move: boarding the microtubule expressway to the nucleus Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy Potential molecular targeting of splice variants for cancer treatment Targeting the androgen receptor in prostate and breast cancer: several new agents in development Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer Overcoming mutation-based resistance to antiandrogens with rational drug design The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance Emerging data on androgen receptor splice variants in prostate cancer Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells Development of the external genitalia: perspectives from the spotted hyena (Crocuta crocuta)Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression.A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.The link between androgen receptor splice variants and castration-resistant prostate cancer.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Androgen receptor splice variants and prostate cancer: From bench to bedside.Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity Mouse models of prostate cancer: picking the best model for the question.Intrinsic disorder in the androgen receptor: identification, characterisation and drugability.

P2860

Q21091046-7C4DBB1F-CB72-4619-9373-CDEDB38D33EA Q21558502-F3399045-3936-4FDF-80A0-8F819E642492 Q24301596-2D73EC25-0249-4B92-AF84-A77DF72B803D Q26739708-5C148AE7-3C55-4CBF-BD8C-30646D99783A Q26740628-E47CFA22-4293-4EB1-A071-638F72A29505 Q26742062-0C7E0C5C-1F25-46F5-B272-71446ACCA89F Q26752873-ED61529B-3BC8-4DB1-88BA-22F65884E1FD Q26777310-4ED5AD3F-8BFE-45DE-BCE2-3B2698ED3277 Q26825402-9B10286D-92A3-4846-865E-64C104E0E462 Q26827515-3E99A0F1-4E9D-4F95-AA16-3D64BB264CAA Q26828810-31AA352E-0205-4C9F-8243-EB821A34B94D Q26858922-B4B6234D-C32C-472F-9356-4D0BC0E47914 Q26862560-3AF7965C-A163-4BD4-8459-C84A2D42312A Q27007098-7939E282-DD44-4A3D-B9B9-B1BBAD6E7347 Q27008529-C2426D3D-9240-474D-BB15-36A1FE3FE55A Q27009424-B7466AA3-D85D-4C00-BD49-49A02DF2733D Q27022288-525B72F1-8985-4FAE-9FB5-933269879961 Q27690285-7B7EBEDC-25E2-4873-B77C-6429866C6DD9 Q27853062-7E48E941-BD6C-484C-AB4A-AA38E23EF14D Q28044590-882A1DFF-17AD-4488-8B92-FF230C9F2D3C Q28076745-34AF2172-0DE6-4474-B6E6-C5058EBDF8BD Q28077830-B9626A26-38E6-43E1-929E-7438F2BEA0A5 Q28539233-265B023A-6A73-4DD5-969B-F891C8EDEA01 Q28657729-3DC50DFA-9AB3-44F9-B157-0BDE9E3AB2A2 Q30357185-F826F6F2-08A2-4C56-9E3C-F7A3EB6B29C3 Q30504566-BA6285CB-5EDB-4DEE-83F3-7AA6B4701717 Q30513836-FD4A4B2F-81D9-4030-82F4-E8D24080D867 Q30528764-8A0A32BF-2AA7-4AAB-816C-2117DDA07DCD Q30544584-0C63BA4C-46F0-4DE3-AD76-AD1F416677A3 Q30554439-940D63CD-413C-42FA-885A-C59218C6C40C Q30577613-62EA5A8D-40CF-4747-9DD2-3591013A981A Q30618562-692A6294-A0A1-49C3-B901-BC78531063A6 Q30831010-AE81EA9E-3B46-4FBC-891E-64A8F4FAD19E Q33567024-6A370C4E-E88F-4CF1-8358-8F8CD7FBC4E7 Q33636318-38621159-7C44-4BF6-AD42-E011FCBB142C Q33688956-2E985D76-5DEC-42B3-B10F-5D1153F2D6A9 Q33752605-89D9FAF8-1E2F-4148-9CCC-2557B5D7481E Q33810134-7B98F1DF-E48E-4876-A54D-D388DD1E9C0C Q33940867-5688F40B-0B69-4CE4-B47E-E774B08FCA75 Q33984776-022EB3B8-ADE8-4A2B-9841-13B20689A18A

P2860

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

http://www.wikidata.org/entity/Q34165500

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Constitutively active androgen ...... full-length androgen receptor

@ast

Constitutively active androgen ...... full-length androgen receptor

@en

Constitutively active androgen ...... full-length androgen receptor

@nl

type

label

Constitutively active androgen ...... full-length androgen receptor

@ast

Constitutively active androgen ...... full-length androgen receptor

@en

Constitutively active androgen ...... full-length androgen receptor

@nl

prefLabel

Constitutively active androgen ...... full-length androgen receptor

@ast

Constitutively active androgen ...... full-length androgen receptor

@en

Constitutively active androgen ...... full-length androgen receptor

@nl

P1433

Q34165500-0975EAC2-B161-4030-B666-83ACBE326A59

P1476

Q34165500-4DFF2EE0-5847-4878-98C1-985A5D7CBE11

P2093

Q34165500-00CBA617-7CFC-4F44-8FEF-EF20655C7503

Q34165500-029EB813-2C01-4F85-ADC9-7963A67A57B0

Q34165500-0880E237-B387-45F0-A1E2-C7CACFFFAC98

Q34165500-21ECC100-8733-4A0E-9383-D5E9791602FF

Q34165500-81C7BF69-D77A-4D05-9497-765CC836CEC2

Q34165500-91E9D076-5289-48B4-9196-5663FA8A5EA0

Q34165500-F5E6767D-84CE-4B04-9109-141D84AADEEA

Q34165500-F6C6E95F-F408-4F0C-9C36-39C7767477AD

P2860

Q34165500-0977CE79-A73E-450C-9F43-3F2CA8049A5C

Q34165500-0DC6DEEA-83FC-48CD-9091-0F35D5EBAD93

Q34165500-1786B0BD-28CA-41C4-9149-3E9FCCA0DF24

Q34165500-1A4D1F5E-1846-4CDA-8ACC-A85954D1C2D1

Q34165500-2B43F14A-593D-4D9D-9BF8-CAA13E2D3D84

Q34165500-318C1893-8C6A-4969-9414-6E219651D9AE

Q34165500-4CE6E684-0FD8-4247-BDE2-8FF3DD49847B

Q34165500-519A4F94-1DA3-4D9C-874E-E69CE3B39BB5

Q34165500-71ACCCBB-48F6-41CD-80CA-831A0DDDB581

Q34165500-725BF349-4B7E-4B07-B7C0-F90B5325856D

P304

Q34165500-5DC00AF1-C6A3-48A7-AD43-236395749887

P31

Q34165500-9BE21E9A-6993-4E7D-B2C0-C0196EED5702

P356

Q34165500-F80EEC9C-7803-45B0-AB62-18FF7B9078B7

P407

Q34165500-97E33893-7D8E-45C3-92DE-9EB0E9D11B32

P433

Q34165500-AE38F1D8-4A48-444F-BDC5-7E54CD063C98

P478

Q34165500-8CB66225-90B8-4EA8-BBAB-D3D74E19554E

P577

Q34165500-3B948F8F-D4D3-4809-B8EB-1FF249D85009

P5875

Q34165500-FE1F09F2-2C60-4100-A911-590E75E87B98

P698

Q34165500-D7971CA8-9EAE-40E7-8563-99328B8264CF

P932

Q34165500-38EC01C6-2827-4509-941F-904ACB4BA5AA

P356

PNAS.1012443107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Constitutively active androgen ...... full-length androgen receptor

@en

P2093

Agnes Viale

http://www.w3.org/2001/XMLSchema#string

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

John Wongvipat

http://www.w3.org/2001/XMLSchema#string

Kwanghee Kim

http://www.w3.org/2001/XMLSchema#string

Minna D Balbas

http://www.w3.org/2001/XMLSchema#string

Nicholas D Socci

http://www.w3.org/2001/XMLSchema#string

Philip A Watson

http://www.w3.org/2001/XMLSchema#string

Yinan F Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

TopHat: discovering splice junctions with RNA-Seq

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Molecular basis of androgen insensitivity.

VCaP, a cell-based model system of human prostate cancer.

Opportunities and challenges in the development of kinase inhibitor therapy for cancer.

P304

16759-16765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1012443107

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46169971

http://www.w3.org/2001/XMLSchema#string

P698

20823238

http://www.w3.org/2001/XMLSchema#string

P932

2947883

http://www.w3.org/2001/XMLSchema#string